BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $327.5556.
Several analysts have recently weighed in on ONC shares. JPMorgan Chase & Co. lifted their price objective on BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Royal Bank Of Canada lifted their price objective on BeOne Medicines from $311.00 to $349.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Wall Street Zen raised BeOne Medicines from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. TD Securities reissued a "buy" rating and set a $334.00 price objective on shares of BeOne Medicines in a report on Thursday, April 24th. Finally, Guggenheim boosted their price target on BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th.
Check Out Our Latest Report on BeOne Medicines
BeOne Medicines Trading Down 3.4%
NASDAQ ONC traded down $10.41 during trading on Friday, reaching $296.82. 343,588 shares of the company's stock were exchanged, compared to its average volume of 437,945. The company has a market capitalization of $32.53 billion, a price-to-earnings ratio of -79.79 and a beta of 0.27. The company has a quick ratio of 1.71, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. BeOne Medicines has a fifty-two week low of $170.36 and a fifty-two week high of $313.29. The stock has a fifty day moving average price of $266.63.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. Equities analysts forecast that BeOne Medicines will post -5.82 EPS for the current fiscal year.
Insiders Place Their Bets
In other BeOne Medicines news, insider Lai Wang sold 4,041 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $302.49, for a total value of $1,222,362.09. Following the completion of the sale, the insider directly owned 259 shares in the company, valued at $78,344.91. This represents a 93.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Oyler sold 27,802 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $253.38, for a total value of $7,044,470.76. The disclosure for this sale can be found here. Insiders sold a total of 144,683 shares of company stock worth $36,294,047 in the last three months. Company insiders own 6.62% of the company's stock.
Institutional Trading of BeOne Medicines
Several institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new position in shares of BeOne Medicines during the second quarter worth approximately $28,000. Farther Finance Advisors LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $39,000. Signaturefd LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $49,000. Parallel Advisors LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $59,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $121,000. Institutional investors own 48.55% of the company's stock.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Further Reading
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access